Asian Spectator


The Times

.

News Lounge Comes to Türkiye, Fostering Dialogue Across Borders

ANTALYA, TURKEY – Media OutReach Newswire – 14 November 2026 – News Lounge, the flagship program of China News Service, welcomed its first group of international guests since its ov...

2024 New Taipei Smart City International Forum Bringing Together Cross-Border Exchange in New Taipei: AI and Sustainability as Dual Engines for Future Development

NEW TAIPEI CITY, TAIWAN - Media OutReach Newswire - 25 June 2024 - On June 19, 2024, at the Hilton Taipei Sinban Hotel, the New Taipei City Government, in collaboration with the internation...

Mira Coral Bay: Branded Property in Ras AI Khaimah (UAE) Reimagined By Mira Developments and Marjan

Located in the heart of Ras Al Khaimah, Mira Coral Bay marks a new chapter in the emirate's luxury lifestyle segment The project of significant investment stands out for its expa...

Media Advisory - Ministers Lametti and Bennettto Hold Media Av...

OTTAWA, ON, June 18, 2021 /PRNewswire-AsiaNet/ -- The Honourable David Lametti, P.C., Q.C., Minister of Justice and Attorney General of Canada, and the Honourable Carolyn Bennett, P.C., Mini...

LONGBRANCH(TM) BOURBON SPARKS CURIOSITY WITH LAUNCH OF NEW CA...

LAWRENCEBURG, Ky., May 11, 2022 /PRNewswire-AsiaNet/ -- The Award-Winning Bourbon Brand Challenges Fans to Question the Conventional with a Zest for Life through Narrative Series of Digital ...

Infineon's New microcontroller optimized for automotive 77 GHz...

MUNICH, Oct. 16, 2019 /PRNewswire-AsiaNet/ -- Infineon Technologies AG (FSE: IFX / OTCQX: IFNNY) will add a new member to its automotive microcontroller family AURIX(TM)[http://www.infineon...

Amari Vang Vieng: Experience Ultimate Relaxation in the Heart of Laos' Mountain and River Paradise

Imagine immersing in nature like never before. Amari Vang Vieng, managed by ONYX Hospitality Group, welcomes guests to the enchanting town of Vang Vieng, surrounded by the stunning valleys a...

FICO Survey: 68% of Vietnamese Prefer to Use Digital Channels ...

HANOI, Vietnam, Mar. 23, 2021 /PRNewswire-AsiaNet/ -- -- Appeal of in-person branch banking fading fast post pandemic Info - https://mma.prnewswire.com/media/1456099/FICO_APAC_banking_Infog...

Taylor Swift Wax Figure Arrives in Singapore for Limited-Time

Following last summer’s historic global launch of 13 Taylor Swift wax figures across four continents, one of the world’s most celebrated icons is now making a dazzling limited-ti...

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

TOKYO, Mar 26, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: E7777) for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL).

This application is based on data from a multicenter, open-label, single-arm Phase II clinical study (study 205) conducted in Japan for patients with relapsed or refractory CTCL or PTCL to evaluate the efficacy and safety of this agent.

This study achieved the primary endpoint and exceeded a predetermined threshold with statistical significance: the objective response rate (ORR) of CTCL and PTCL patients in total (n=36) was 36.1% (95% confidence interval (CI): 20.8-53.8). The ORRs of each subtype were 31.6% (95% CI:12.6-56.6) for CTCL (n=19) and 41.2% (95%CI: 18.4-67.1) for PTCL (n=17).

The five most frequent adverse events observed in this study were increased aspartate aminotransferase (AST) (89.2%), increased alanine aminotransferase (ALT) (86.5%), hypoalbuminaemia (70.3%), lymphopenia (70.3%), and pyrexia (51.4%).

Denileukin diftitox (genetic recombinant) is a fusion protein of the receptor-binding portion of interleukin-2 (IL-2) and diphtheria toxin that specifically binds to the IL-2 receptor on the surface of tumoral lymphocyte. The antitumor effect of denileukin diftitox depends on the intracellular delivery of diphtheria toxin which inhibits protein synthesis and induces cell death. The agent has been evaluated as a drug with high medical need by the "Study Group for Unapproved Drugs/Off-Label Drugs for High Medical Needs"(1), and Eisai has been requested to develop it by the Ministry of Health, Labour and Welfare.

Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. Eisai aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals.

(1) The Study Group set up within the Ministry of Health, Labour and Welfare with the purpose of contributing to enhancing the development of drugs and indications that have not been approved in Japan (unapproved drugs/off-label drugs) by pharmaceutical companies. In addition to evaluating the medical needs of unapproved drugs/off-label drugs, their responsibilities include evaluating the applicability of the drug to an Application with Public Knowledge, and the adequacy of additional clinical studies that need to be conducted for filing applications for approval, and so on.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:Media Inquiries:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegalmarsbahisuk casinos not on gamstophttps://www.capitolcitycinema.org/grandpashabet resmi girişStreamEastStreamEast